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An 82-year-old woman was evaluated for watery chronic 
diarrhea. Her past medical history was irrelevant. During the 
last 4 months she had around 5 bowel movements daily, without 
blood, present also during nighttime. Laboratory analysis showed 
mild anemia (hemoglobin 10.4g/dL), mild leucocytosis (10,300/
μL), and increased C-reactive protein level (4.59mg/dL). The 
stool cultures, including ova and parasites, and Clostridium 
difficile were negative. She was initially empirically treated with 
probiotics, loperamide and cholestyramine with partial resolution 
of symptoms. An ileocolonoscopy performed two months later 
revealed deep ulcerations (Fig. 1) and various cicatricial areas (Fig. 
2) involving all colorectal mucosa. The histological examination 
demonstrated slight architectural distortion with regenerative 
aspects; lymphoplasmacytic infiltrate, eosinophils and neutrophils 
were depicted in the lamina propria. In the necrotic areas, 
rhomboyd orange/eosinophilic crystals (Fig. 3, H&E 40x), without 
„fish-scale” pattern, were found. These features were compatible 
with crystal-associated colitis induced by cholestyramine.
This crystal-associated colitis is very rare, and to our 
knowledge, only one case reported cholestyramine as causative 
agent [1]. The responsible crystals are: resins (namely kayexalate) 
and sevelamer, with different characteristics revealed by 
histology. Kayexalate crystals show a quite specific morphology: 
rhomboid or triangular, basophilic, with “fish-scale” pattern [2]. 
Cholestyramine crystals appear orange or basophilic, angulated, 
and are distinguished from kayexalate by their greater opacity 
and lack of “fish-scale” pattern. Both crystals stain red with 
periodic acid-Schiff staining: kayexalate is red with an acid-fast 
staining, whereas cholestyramine is pink [2].
Sevelamer and kayexalate crystals are associated with chronic 
renal failure and show “fish-scale” pattern; however, sevelamer 
has a two-toned color (yellow/pink), and are magenta with the 
acid-fast stain [3]. 
IMAGE OF THE ISSUE
The time between the drug intake and the appearance of 
symptoms or the diagnosis of colitis is not yet fully known, 
especially for cholestyramine. For kayexalate, Harel et al. [4] 
analyzed a total of 58 cases, of which 51 were given kayexalate 
for acute treatment of hyperkalemia (with 5 patients taking only 
a single dose) and 7 were on treatment for more than 1 month. 
The median time to symptoms, in the case of patients taking 
kayexalate for acute treatment, was 2 days (1-5 days).
Attention should be paid to the clinical history with an 
adequate medication review, because of the overlapping of color 
and morphology of these crystals [3].
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